Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Bifidobacterium breve M-16V regulates the autonomic nervous system via the intestinal environment: A double-blind, placebo-controlled study.

  • 2024-03
  • Behavioural brain research 460
    • Natsumi Mutoh
    • Masamichi Moriya
    • Chendong Xu
    • Kumiko Kato
    • Satoshi Arai
    • Noriyuki Iwabuchi
    • Miyuki Tanaka
    • Yin Jinghua
    • Ronko Itamura
    • Kaoru Sakatani
    • Shinichi Warisawa

Study Design

Type
Randomized Controlled Trial (RCT)
Population
humans
Methods
randomized controlled trial, 6 weeks of 20 billion cells/day Bifidobacterium breve M-16 V, near-infrared spectroscopy (NIRS) assessments
We conducted a randomized controlled trial to investigate the potential of Bifidobacterium breve M-16 V to improve mood in humans. In this evaluation, we incorporated the use of near-infrared spectroscopy (NIRS), which has been used to evaluate mood states in studies with small sample sizes. Participants were given B. breve M-16 V (20 billion cells/day) for 6 weeks, and their mood state was assessed before and after ingestion. NIRS data were collected at rest and during a mental arithmetic task (under stress). Intake of B. breve M-16 V decreased the heart rate under stress and increased levels of the GABA-like substance pipecolic acid in stool samples. In addition, B. breve M-16 V improved mood and sleep scores in participants with high anxiety levels. These results suggest that B. breve M-16 V affects the metabolites of the gut microbiota and has the potential to modulate the autonomic nervous system and to improve mood and sleep.

Research Insights

Back to top